Abstract:Background: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are available to the majority of people with CF in the United States; little is known about pregnancy outcomes with modulator use. The aim of this retrospective study was to determine the impact of CFTR modulators on maternal outcomes. Research question: Does pregnancy differentially affect outcomes in female subjects with CF with and without CFTR modulator exposure? Study design and methods: Data on pregnancies from 2010 to 2021 were collected from 11 US adult CF centers. Multivariable longitudinal regression analysis was performed to assess whether changes in percent predicted FEV1 (ppFEV1), BMI, pulmonary exacerbations (PEx), and Pseudomonas aeruginosa prevalence differed from prior to, during, and following pregnancy according to CFTR modulator use while adjusting for confounders. Infant outcomes are also described based on maternal modulator use. Results: Among 307 pregnancies, mean age at conception was 28.5 years (range, 17-42 years), prepregnancy ppFEV1 was 74.2, and BMI was 22.3 kg/m2. A total of 114 pregnancies (37.1%) had CFTR modulator exposure during pregnancy (77 with highly effective modulator therapy [HEMT] and 37 with other modulators). The adjusted mean change in ppFEV1 from prepregnancy to during pregnancy was -2.36 (95% CI, -3.56 to -1.16) in the unexposed group and 2.60 (95% CI, 0.23 to 4.97) in the HEMT group, with no significant change from during pregnancy to 1 year postpregnancy. There was an overall decline in ppFEV1 from prepregnancy to postpregnancy in the no modulator group (-2.56; 95% CI, -3.62 to -1.49) that was not observed in the HEMT group (1.10; 95% CI, -1.13 to 3.34). PEx decreased from prepregnancy to postpregnancy in the HEMT group, and BMI increased from prepregnancy to during pregnancy in all groups but with no significant change postpregnancy. Missing infant outcomes data precluded firm conclusions. Interpretation: We observed superior pregnancy and postpregnancy pulmonary outcomes in individuals who used HEMT, including a preservation of ppFEV1, compared with those unexposed to HEMT.

Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy

Use of CFTR modulators in pregnancy: new information for neonatal, paediatrics and midwifery teams

A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy

CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis

Obstetric and neonatal outcomes among pregnant patients with cystic fibrosis

Pregnancy in People With Cystic Fibrosis Treated With Highly Effective Modulator Therapy

Parenthood impacts short-term health outcomes in people with cystic fibrosis

"Shifting sands in cystic fibrosis": impacts of CFTR modulators on reproductive health in people with cystic fibrosis and challenges related to in utero exposure

Maternal and fetal outcomes in multiparous women with Cystic Fibrosis

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

A Survey of Pregnancy Outcomes for Women of Childbearing Age with Inflammatory Bowel Disease in South China

A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators

Assessing the health impacts of parenthood on people with cystic fibrosis: the HOPeCF prospective cohort protocol

Fertility preservation in women with cystic fibrosis pre‐lung transplantation: A mixed methods study

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis

Outcomes of Modulator Therapy Discontinued After Short‐Term Use in Adult Cystic Fibrosis

Clinical outcomes at 9–10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome

Exploring perceptions of and decision‐making about CFTR modulators

Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis

Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians